Oncothyreon initiates Phase 1 ONT-380 trial

|By:, SA News Editor

Oncothyreon (ONTY +2.1%) initiates a Phase 1 trial of a ONT-380/ Herceptin combo in patients with brain metastases from HER2+ breast cancer. ONT-380 is developed in collaboration with Array BioPharma (ARRY +3.6%).

The objective of the trial will be to determine "the maximum-tolerated dose and recommended Phase 2 dose and schedule." (PR)

Relevant drugs in HER2+ breast cancer: GlaxoSmithKline's (GSK +1.6%) Tykerb, Puma Biotechnology's (PBYI +4%) neratinib.